- Home
- NPCE
NPCE
Neuropace Inc.
as 05-23-2025 4:00pm EST
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 358.3M | IPO Year: | 2021 |
| Target Price: | $14.67 | AVG Volume (30 days): | 323.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.45 - $18.98 | Next Earning Date: | 05-13-2025 |
| Revenue: | $84,306,000 | Revenue Growth: | 22.05% |
| Revenue Growth (this year): | 20.74% | Revenue Growth (next year): | 12.47% |
Latest Neuropace Inc. News
NPCE Breaking Stock News: Dive into NPCE Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Simply Wall St.
9 days ago
NeuroPace, Inc.'s (NASDAQ:NPCE) large institutional owners must be happy as stock continues to impress, up 29% over the past week
Simply Wall St.
9 days ago
NeuroPace First Quarter 2025 Earnings: Beats Expectations
Thomson Reuters StreetEvents
10 days ago
Q1 2025 Neuropace Inc Earnings Call
GuruFocus.com
11 days ago
NeuroPace Inc (NPCE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Zacks
11 days ago
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
11 days ago
NeuroPace Inc.: Q1 Earnings Snapshot
GlobeNewswire
11 days ago
NeuroPace Reports First Quarter 2025 Financial Results
Compare NPCE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NPCE Neuropace Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.